Search Market Research Report
Hemoglobinopathies Market Size, Share Global Analysis Report, 2020–2026
Hemoglobinopathies Market by Indication (Sickle cell disease, Alpha Thalassemia, Beta Thalassemia and Others), Therapy (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant and Others), Diagnosis (Blood testing, Genetic testing, Pre-implantation Genetic Diagnosis (PGD) and Other), and end user (Hospitals, Diagnostic laboratories, Clinics and Other End-user): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecast 2020–2026
Industry Insights
[185+ Pages Report] According to the report published by Facts Factors, the global hemoglobinopathies market size was worth around USD 5,423.5 million in 2019 and is predicted to grow to around USD 13,465.2 million by 2026 with a compound annual growth rate (CAGR) of roughly 10.34% between 2020 and 2026. The report analyzes the global hemoglobinopathies market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the hemoglobinopathies market.
This specialized and expertise oriented industry research report scrutinizes the technical and commercial business outlook of the Hemoglobinopathies industry. The report analyzes and declares the historical and current trends analysis of the Hemoglobinopathies industry and subsequently recommends the projected trends anticipated to be observed in the Hemoglobinopathies market during the upcoming years.
The Hemoglobinopathies market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire Hemoglobinopathies market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Million) from FY 2016 – 2026.
Key Insights from Primary Research
- According to the primary CXO’s of the global hemoglobinopathies market, the market is estimated to witness a substantial growth of nearly 13.42% over the forecast period.
- The market was valued at USD 5,423.5 million, in 2019 and is expected to be valued over USD 13,465.2 million.
- On the basis of the therapy segment, blood transfusion therapy held the largest market share. Rising policy measures to increase the number of blood donors are a high impact making engine for the demand for hemoglobinopathies.
- Geography-wise, the Asia Pacific market is likely to be the fastest-growing region for hemoglobinopathies over the forecast period.
- By geography, the North America region headed the market with a share of above 32.5%, in 2019.
Key Recommendations from Analysts
- Improved R&D investments are projected to contribute to demand development for new therapies. The National Heart, Lung, and Blood Institute (NHLBI), part of the National Health Institutes (NIH), is funding SCD research programs to find new methods of identifying and managing the disease and enhancing patient outcomes.
- The strategic developments such as regional expansion, product innovations and on-going research and developments by the major companies such as CytoTherm Alnylam Pharmaceuticals, bluebird bio Inc., Celgene Corporation is likely to boom the market’s growth over the upcoming years.
- Our analysts advise that the Asia Pacific region will probably witness a significant growth attributed to the growing demand for hemoglobinopathies from the developing countries like India.
- Expansion of manufacturing plants or distribution channels of pharmaceuticals companies especially in the emerging market is predicted to fuel the demand for hemoglobinopathies drug in the developing economies over the forecast years.
The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the Hemoglobinopathies industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.
Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the Hemoglobinopathies industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the Hemoglobinopathies market.
The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the Hemoglobinopathies industry. The Hemoglobinopathies market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.
The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the Hemoglobinopathies sector. Key strategic developments in the Hemoglobinopathies market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the Hemoglobinopathies market are appropriately highlighted in the report.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 5,423.5 Million |
Projected Market Size in 2026 |
USD 13,465.2 Million |
CAGR Growth Rate |
10.34% CAGR |
Base Year |
2019 |
Forecast Years |
2020-2026 |
Key Market Players |
Alnylam Pharmaceuticals, bluebird bio Inc., Celgene Corporation, Emmaus Life Sciences Inc., Gamida Cell, Global Blood Therapeutics, Prolong Pharmaceuticals, Sangamo, Therapeutics Inc., Sanofi and Others |
Key Segment |
By Indication, Therapy, Diagnosis, End-user, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
The Hemoglobinopathies market research report delivers an acute valuation and taxonomy of the Hemoglobinopathies industry by practically splitting the market on the basis of different types, category and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the Hemoglobinopathies industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Further, country-wise data for the Hemoglobinopathies industry is provided for the leading economies of the world.
Hemoglobinopathies are caused by defects in the genes and by anemia. Default hemoglobin formation is observed in three conditions, such as hemoglobin molecule structural defects, reduced production of one of the two hemoglobin molecule subunits, and abnormal interactions of otherwise safe subunits. There can be serious or mild illnesses. Genetic diagnosis, genetic and blood testing, electrophoresis of alkaline and acid gel, hemoglobin electrophoresis, genetic prenatal testing, and chromatography exchange of ions HbA2 are the most common tools/tests for diagnosis of hemoglobinopathy and thalassemia.
The Hemoglobinopathies market is segmented into indication, therapy, diagnosis, end-user, and region segment. The indication segment is segmented into sickle cell disease, alpha-thalassemia, beta-thalassemia, and others. The therapy segment is divided into iron chelation therapy, blood transfusion, bone marrow transplant, and others. The Diagnosis segment is bifurcated into blood testing, genetic testing, pre-implantation genetic diagnosis (PGD), and Others. The end-user segment is segmented into hospitals, diagnostic laboratories, clinics, and other end-user.
Some of the essential players operating in the Hemoglobinopathies Market :
- Alnylam Pharmaceuticals
- bluebird bio Inc.
- Celgene Corporation
- Emmaus Life Sciences Inc.
- Gamida Cell
- Global Blood Therapeutics
- Prolong Pharmaceuticals
- Sangamo
- Therapeutics Inc.
- Sanofi
The taxonomy of the Hemoglobinopathies industry by its scope and segmentation is as follows:
Indication Segment Analysis
- Sickle cell disease
- Alpha Thalassemia
- Beta Thalassemia
- Others
Therapy Segment Analysis
- Blood Transfusion
- Iron Chelation Therapy
- Bone Marrow Transplant
- Others
Diagnosis Segment Analysis
- Blood testing
- Genetic testing
- Pre-implantation Genetic Diagnosis (PGD)
- Other
End-user Segment Analysis
- Hospitals
- Diagnostic laboratories
- Clinics
- Other End-use
Regional Segmentation Analysis
- North America
- The U.S.
- Canada
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
Industry Major Market Players
- Alnylam Pharmaceuticals
- bluebird bio Inc.
- Celgene Corporation
- Emmaus Life Sciences Inc.
- Gamida Cell
- Global Blood Therapeutics
- Prolong Pharmaceuticals
- Sangamo
- Therapeutics Inc.
- Sanofi
Copyright © 2023 - 2024, All Rights Reserved, Facts and Factors